Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 197

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 197
---
 development;

•other costs in seeking regulatory approval of our product candidates; and

•direct costs and allocated costs related to laboratories and facilities, depreciation expense, information technology and other overhead.

Up-front fees incurred in obtaining technology licenses for research and development activities, as well as associated milestone payments, are charged to research and development expense as incurred if the technology licensed has no alternative future use.

We expect to continue to incur significant research and development expenses for the foreseeable future as we continue the development of our product candidates and engage in early research and development for prospective product candidates and new technologies. The following table summarizes our research and development expenses incurred during the years ended December 31, 2024, 2023 and 2022 (in thousands):

    Years Ended December 31,

    2024

    2023*

    2022*

    Direct Expenses

    ABBV-RGX-314
     
    $
    36,401

    $
    24,453

    $
    50,246

    RGX-202

    14,419

    10,803

    17,102

    RGX-121

    12,143

    19,128

    8,436

    Other product candidates

    7,103

    9,908

    6,663

    Total direct expenses

    70,066

    64,292

    82,447

    Unallocated Expenses

    Platform and early research

    27,885

    46,045

    48,950

    Personnel

    65,950

    73,356

    67,466

    Facilities

    11,410

    11,653

    10,284

    Stock-based compensation

    17,985

    20,568

    21,368

    Depreciation and amortization

    15,226

    16,352

    11,938

    Total unallocated expenses

    138,456

    167,974

    160,006

    Total research and development
     
    $
    208,522

    $
    232,266

    $
    242,453

* Certain amounts reported in prior years have been reclassified to conform to the current year's presentation.

Direct expenses related to the development of ABBV-RGX